Unaudited Financial Results of the Company along with Limited Review Report for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.9 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Roselabs Finance reported Q3 FY26 revenue from operations of ₹120.75 lakhs, a sharp jump from ₹70.91 lakhs in Q3 FY25 (roughly 70% growth), while total nine-month income came in at ₹120.75 lakhs (vs about ₹1.68 lakhs in 9M FY25, which was almost entirely other income). The nine-month loss narrowed significantly to ₹14.33 lakhs from ₹24.63 lakhs in the year-ago period, helped by lower employee and other expenses. Q3 alone posted a loss of ₹3.67 lakhs versus ₹10.84 lakhs a year earlier. Statutory auditor MSKA & Associates issued an unmodified review report. The balance sheet still shows accumulated losses of ₹1,472.76 lakhs against share capital of just ₹1,000 lakhs, implying negative net worth, and a Section 230 merger scheme remains in process.
The sharp revenue jump and shrinking loss are positive signals, but the company continues to bleed cash and has fully eroded its net worth, making the pending merger scheme critical to its survival. Retail investors should treat this as a high-risk, sub-scale entity with turnaround characteristics rather than a stable investment.